NCT00629148View on ClinicalTrials.gov

Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC)

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

December 31, 2010

Conditions
Breast CancerMetastasis, Neoplasm
Interventions
DRUG

Vinorelbine and Capecitabine

Vinorelbine 25mg/m2 D1, D8 q3w Capecitabine 1000mg/m2 D1-D14 q3w

DRUG

Vinorelbine and Capecitabine

Vinorelbine 25mg/m2 D1, D8 q3w. When disease progression or untolerated toxicity occurs, Capecitabine 1000mg/m2 D1-D14 q3w

Trial Locations (1)

200032

Fudan University Cancer Hospital, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT00629148 - Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC) | Biotech Hunter | Biotech Hunter